MedTrace Logo

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

NCT00454805 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2016-08-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.

Conditions

Interventions

DRUG

AZD2171

Oral tablet

DRUG

Fulvestrant

intramuscular injection

Sponsors & Collaborators

Principal Investigators

  • Bijoyesh Mookerjee, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-12-31
Completion
2016-04-30

Countries

  • United States
  • Australia
  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00454805 on ClinicalTrials.gov